Neuroimmune aspects of sjögren's syndrome: Role of vip/vpac system in immune and salivary gland epithelial cell function

Current Pharmaceutical Design

Volumn 20, Issue 29, 2014, Pages 4760-4765

  Vanesa, Hauk ^a   Mario, Calafat ^a   Esteban, Grasso ^a   Laura, Fraccaroli ^a   Daniel, Paparini ^a   Rosanna, Ramhorst ^a   Claudia, Pérez Leirós ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Salivary epithelial cells; Sj gren syndrome; Vasoactive intestinal peptide

Indexed keywords

VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; CELL FUNCTION; DISEASE SEVERITY; EPITHELIUM CELL; HOMEOSTASIS; HUMAN; IMMUNITY; IMMUNOMODULATION; MACROPHAGE; NONHUMAN; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL; SALIVARY GLAND FUNCTION; SJOEGREN SYNDROME; ANIMAL; DISEASE MODEL; IMMUNE SYSTEM; IMMUNOLOGY; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SALIVARY GLAND;

ANIMALS; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; HUMANS; IMMUNE SYSTEM; MICE; SALIVARY GLANDS; SJOGREN'S SYNDROME; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84906281940     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140130203636     Document Type: Article

References (95)

1. Konttinen YT, Porola P, Konttinen L, Laine M, Poduval P. Immu-nohistopathology of Sjögren's syndrome. Autoimmunity Rev 2006; 6: 16-20.
2. García-Carrasco M, Fuentes-Alexandro S, Escárcega RO, Salgado G, Riebeling C, Cervera R. Pathophysiology of Sjögren's syndrome. Arch Med Res 2006; 37: 921-932.
3. Konttinen YT, Fuellen G, Bing Y, et al. Sex steroids in Sjögren's syndrome. J Autoimmun 2012; 39: 49-56.
4. Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthr Rheum 2010; 62: 960-968.
5. Fox RI. The salivary gland epithelial cell in Sjogren's Syndrome: what are the steps involved in wounding or killing their secretory function? J Rheumatol 2012; 39: 1117-1119.
6. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjögren syndrome. Arch Int Med 2004; 164: 1275-1284.
7. Mavragani CP, Moutsopoulos NM, Moutsopoulos HM. The management of Sjögren's syndrome. Nat Clin Pract Rheum 2006; 2: 252-261.
8. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-558.
9. Shiboski SC, Shiboski CH, Criswell LA, et al. American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthr Care Res 2011;64(4):475-487.
10. Ramos-Casals M BZP, Sisó-Almirall A, Bosch X, Tzioufas AG. Topical and systemic medications for the treatment of primary Sjögren's syndrome. Nat Rev Rheumatol 2012; 8: 399-411.
11. Ng WF, Bowman SJ. Biological therapies in primary Sögren' s syndrome Expert Opin Biol Ther 2011; 11: 921-936.
12. Jonsson R, Vogelsang P, Volchenkov R, Espinosa A, Wahren-Herlenius M, Appel S. The complexity of Sjögren's syndrome: Novel aspects on pathogenesis. Immunol Lett 2011;141(1):1-9.
13. Voulgarelis M, Tzioufas AG. Pathogenetic mechanisms in the initiation and perpetuation of Sjögren's syndrome. Nat Rev Rheu-matol 2010; 6: 529-537.
14. Larsen M, Yamada KM, Musselmann K. Systems analysis of salivary gland development and disease. Wiley Interdisciplinary Rev Systems Biol Med 2010; 2: 670-682.
15. Manoussakis MN, Kapsogeorgou EK. The role of intrinsic epithelial activation in the pathogenesis of Sjögren's syndrome. J Auto-immun 2010; 35: 219-224.
16. Mitsias DI, Kapsogeorgou EK, Moutsopoulos HM. Sjögren's syndrome: why autoimmune epithelitis? Oral Dis 2006; 12: 523-532.
17. Fox RI, Stern M. Sjögren's syndrome: mechanisms of pathogenesis involve interaction of immune and neurosecretory systems. Scand J Rheumatol Supplement 2002; 116: 3-13.
18. Thorburn A. Apoptosis and autophagy: regulatory connections between two supposedly different processes. Apoptosis 2008; 13: 1-9.
19. Tomasini R, Samir AA, Carrier A, et al. TP53INP1s and ho-meodomain-interacting protein kinase-2 (HIPK2) are partners in regulating p53 activity. J Biol Chem 2003; 278: 37722-3729.
20. Cano CE, Gommeaux J, Pietri S, et al. Tumor protein 53-induced nuclear protein 1 is a major mediator of p53 antioxidant function. Cancer Res 2009; 69: 219-226.
21. Tomasini R, Seux M, Nowak J, et al. TP53INP1 is a novel p73 target gene that induces cell cycle arrest and cell death by modulating p73 transcriptional activity. Oncogene 2005; 24: 8093-8104.
22. Bacman S, Perez Leiros C, Sterin-Borda L, Hubscher O, Arana R, Borda E. Autoantibodies against lacrimal gland M3 muscarinic acetylcholine receptors in patients with primary Sjögren's syndrome. Invest Ophtalmol Vis Sci 1998; 39: 151-156.
23. Pérez Leirós C, Sterin-Borda L, Hubscher O, Arana R, Borda ES. Activation of nitric oxide signaling through muscarinic receptors in submandibular glands by primary Sjögren syndrome antibodies. Clin Immunol 1999; 90: 190-195.
24. Park K, Haberberger RV, Gordon TP, Jackson MW. Antibodies interfering with the type 3 muscarinic receptor pathway inhibit gastrointestinal motility and cholinergic neurotransmission in Sjögren's syndrome. Arthr Rheum 2011; 63: 1426-1434.
25. Nguyen KH, Brayer J, Cha S, et al. Evidence for antimuscarinic acetylcholine receptor antibody-mediated secretory dysfunction in nod mice. Arthr Rheum 2000; 43: 2297-2306.
26. Nakamura Y, Wakamatsu E, Matsumoto I, et al. High prevalence of autoantibodies to muscarinic-3 acetylcholine receptor in patients with juvenile-onset Sjögren syndrome. Ann Rheum Dis 2008; 67: 136-137.
27. Delaleu N, Immervoll H, Cornelius J, Jonsson R. Biomarker profiles in serum and saliva of experimental Sjögren's syndrome: associations with specific autoimmune manifestations. Arthr Res Ther 2008; 10: R22-R.
28. Appel S, Le Hellard S, Bruland O, et al. Potential association of muscarinic receptor 3 gene variants with primary Sjogren's syndrome. Ann Rheum Dis 2011; 70: 1327-1329.
29. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macro-phage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23: 549-555.
30. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 5: 953-964.
31. Kurosaka K, Takahashi M, Watanabe N, Kobayashi Y. Silent cleanup of very early apoptotic cells by macrophages. J Immunol 2003; 171: 4672-4679.
32. Mosser DM, Edwards JP. Exploring the full spectrum of macro-phage activation. Nat Rev Immunol 2008; 8: 958-969.
33. Brancato SK, Albina JE. Wound Macrophages as Key Regulators of Repair. AJPA 2011; 178: 19-25.
34. Fairweather D, Cihakova D. Alternatively activated macrophages in infection and autoimmunity. J Autoimmun 2009; 33: 222-230.
35. Biswas SK, Chittezhath M, Shalova IN, Lim JY. Macrophage polarization and plasticity in health and disease. Immunol Res 2012; 53: 11-24.
36. Galli SJ BN, Wynn TA. Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils. Nat Immunol 2011; 12: 1035-1044.
37. Freire-Garabal M NMJ, Balboa J, López-Delgado P, et al. Serotonin upregulates the activity of phagocytosis through 5-HT1A receptors Br J Pharmacol 2003; 139: 457-463.
38. Delgado M, Munoz-Elias EJ, Martinez C, Gomariz RP, Ganea D. VIP and PACAP38 modulate cytokine and nitric oxide production in peritoneal macrophages and macrophage cell lines. Ann N Y Acad Sci 1999; 897: 401-414.
39. Su L, Sun Y, Ma F, Lü P, Huang H, Zhou J. Progesterone inhibits Toll-like receptor 4-mediated innate immune response in macro-phages by suppressing NF-kappaB activation and enhancing SOCS1 expression. Immunol Lett 2009; 125: 151-155.
40. Couvineau A, Laburthe M. VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins. Br J Pharmacol 2011; 166: 42-50.
41. Harmar AJ FJ, Gozes I, Laburthe M, et al. Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR Review 1. Br J Pharmacol 2012; 166:4-17
42. Onoue S, Misaka S, Yamada S. Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications. Naunyn-Schmiedeberg's Arch Pharmacol 2008; 377: 579-590.
43. Leceta J, Gomariz RP, Martinez C, Carrión M, Arranz A, Juarranz Y. Vasoactive intestinal peptide regulates Th17 function in autoimmune inflammation. Neuroimmunomodulation 2007; 14: 134-138.
44. Gressens P MS, Hill JM, Brenneman DE, Gozes I, Fridkin M, Evrard P. Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain. J Clin Invest 1997; 100: 390-397.
45. Månsson B, Nilsson BO, Ekström J. Effects of repeated infusions of substance P and vasoactive intestinal peptide on the weights of salivary glands subjected to atrophying influences in rats. Br J Pharmacol 1990; 101: 853-858.
46. Ekström J NB, Rosengren E. Substance P and vasoactive intestinal peptide influence polyamine metabolism in salivary glands of the rat. Acta Physiol Scand 1989; 136: 427-433.
47. Ekström J MB, Tobin G. Vasoactive intestinal peptide evoked secretion of fluid and protein from rat salivary glands and the development of supersensitivity. Acta Physiol Scand 1983; 119: 169-175.
48. Lara-Marquez M, O'Dorisio M, O'Dorisio T, Shah M, Karacay B. Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells. J Immunol 2001; 166: 2522-2530.
49. Martinez C, Delgado M, Abad C, Gomariz RP, Ganea D, Leceta J. Regulation of VIP production and secretion by murine lymphocytes. J Neuroimmunol 1999; 93: 126-138.
50. Li JMSL, Hossain MS, Giver CR, et al. Absence of vasoactive intestinal peptide expression in hematopoietic cells enhances Th1 polarization and antiviral immunity in mice. J Immunol 2011; 187: 1057-1065.
51. Lodde BM, Mineshiba F, Wang J, et al. Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome. Ann Rheum Dis 2006; 65: 195-200.
52. Delgado M, Toscano MG, Benabdellah K, et al. In vivo delivery of lentiviral vectors expressing vasoactive intestinal peptide complementary DNA as gene therapy for collagen-induced arthritis. Arthr Rheum 2008; 58: 1026-1037.
53. Gonzalez-Rey E, Delgado M. Vasoactive intestinal peptide and regulatory T-cell induction: a new mechanism and therapeutic potential for immune homeostasis. Trends Mol Med 2007; 13: 241-251.
54. Gomariz RP, Arranz A, Juarranz Y, et al. Regulation of TLR expression, a new perspective for the role of VIP in immunity. Pep-tides 2007; 28: 1825-1832.
55. Delgado MAC, Martinez C, Leceta J, Gomariz RP. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 2001; 7: 563-568.
56. Yadav M, Goetzl EJ. Vasoactive intestinal peptide-mediated Th17 differentiation: an expanding spectrum of vasoactive intestinal pep-tide effects in immunity and autoimmunity. Ann N Y Acad Sci 2008; 1144: 83-89.
57. Rosignoli FTM, Juarranz Y, García-Gómez M, et al. VIP and Tolerance Induction in Autoimmunity. Ann N Y Acad Sci 2006; 1070: 525-530.
58. Toscano MG DM, Kong W, Martin F, Skarica M, Ganea D. Dendritic cells transduced with lentiviral vectors expressing VIP differentiate into VIP-secreting tolerogenic-like DCs. Mol Ther 2010; 182:1035-1045.
59. Juarranz MG SB, Torroba M, Gutierrez-Cañas I, et al. Vasoactive intestinal peptide modulates proinflammatory mediator synthesis in osteoarthritic and rheumatoid synovial cells. Rheumatology (Oxford) 2004; 43: 416-422
60. Arranz A, Abad C, Juarranz Y, Leceta J, Martinez C, Gomariz RP. Vasoactive intestinal peptide as a healing mediator in Crohn's disease. Neuroimmunomodulation 2008; 15: 46-53.
61. Juarranz Y, Gutiérrez-Cañas I, Santiago B, Carrión M, Pablos JL, Gomariz RP. Differential expression of vasoactive intestinal pep-tide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts. Arthr Rheum 2008; 58: 1086-1095.
62. Delgado MGRE, Ganea D. The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells. J Immunol 2005; 175: 7311-7324.
63. Chorny AGRE, Fernandez-Martin A, Pozo D, Ganea D, Delgado M. Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. Proc Natl Acad Sci USA 2005; 102: 13562-13567.
64. Pozo DGRE, Chorny A, Anderson P, Varela N, Delgado M. Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disorders. Peptides 2007; 28: 1833-1846.
65. Said SI HS, Dickman KG, Szema AM, et al. Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation 2007; 115: 1260-1268.
66. Said SI HS, Gonzalez Bosc L. Asthma and pulmonary arterial hypertension: do they share a key mechanism of pathogenesis? Eur Respir J 2010; 35: 730-734.
67. Voice JKGC, Kong Y, Bangale Y, Paul S, Goetzl EJ. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice. J Immunol 2003; 170: 308-314.
68. Delgado MPD, Martinez C, Garrido E, Leceta J, Calvo JR, Gomariz RP. Characterization of gene expression of VIP and VIP1-receptor in rat peritoneal lymphocytes and macrophages. Regul Pept 1996; 62: 161-166.
69. Leceta JMC, Delgado M, Garrido E, Gomariz RP. Expression of vasoactive intestinal peptide in lymphocytes: a possible endogenous role in the regulation of the immune system. Adv Neuroim-munol 1996; 6: 29-36.
70. Vassiliou EJX, Delgado M, Ganea D. TH2 lymphocytes secrete functional VIP upon antigen stimulation. Arch Physiol Biochem 2001; 109: 365-368.
71. Rosignoli F, Goren NB, Pe C. Alterations in Nitric Oxide Synthase Activity and Expression in Submandibular Glands of NOD Mice. Clin Immunol 2001; 101: 86-93.
72. Rosignoli F, Pe C. Nitric oxide synthase I and VIP-activated signaling are affected in salivary glands of NOD mice. J Neuroimmunol 2002; 130: 109-116.
73. Rosignoli F, Roca V, Meiss R, Leceta J, Gomariz RP, Pérez Leirós C. Defective signalling in salivary glands precedes the autoimmune response in the non-obese diabetic mouse model of sialadenitis. Clin Exp Immunol 2005; 142: 411-418.
74. Calafat M, Larocca L, Roca V, Pérez Leirós C. NOD mice exocri-nopathy: towards a neuroimmune link. Neuroimmunomodulation 2007; 14: 175-181.
75. Roescher N, Lodde B, Vosters J, et al. Temporal changes in salivary glands of non-obese diabetic mice as a model for Sjögren's syndrome. Oral Dis 2011; 18: 96-106.
76. Jonsson MV, Delaleu N, Brokstad KA, Berggreen E, Skarstein K. Impaired salivary gland function in NOD mice: association with changes in cytokine profile but not with histopathologic changes in the salivary gland. Arthr Rheum 2006; 54: 2300-2305.
77. Lavoie TN, Lee BH, Nguyen CQ. Current concepts: mouse models of Sjögren's syndrome. J Biomed Biotechnol 2011; 2011: 549107.
78. Nguyen CQ, Kim H, Cornelius JG, Peck AB. Development of Sjogren's syndrome in nonobese diabetic-derived autoimmune-prone C57BL/6.NOD-Aec1Aec2 mice is dependent on complement component-3. J Immunol 2007; 179: 2318-2329.
79. Strietzel FP, Lafaurie GI, Mendoza GRB, et al. Efficacy and safety of an intraoral electrostimulation device for xerostomia relief: a multicenter, randomized trial. Arthr Rheum 2011; 63: 180-190.
80. Wolff A, Fox PC, Porter S, Konttinen YT. Established and novel approaches for the management of hyposalivation and xerostomia. Curr Pharm Des 2012; 18: 5515-5521.
81. Konttinen YT HM, Kemppinen P, Segerberg M, et al. Peptide-containing nerves in labial salivary glands in Sjögren's syndrome. Arthritis Rheum 1992; 35: 815-820.
82. Monaghan TK, Mackenzie CJ, Plevin R, Lutz EM. PACAP-38 induces neuronal differentiation of human SH-SY5Y neuroblas-toma cells via cAMP-mediated activation of ERK and p38 MAP kinases. J Neurochem 2008; 104: 74-88.
83. Spong CY, Lee SJ, Cune SKMC, et al. Maternal Regulation of Embryonic Growth: The Role of Vasoactive Intestinal Peptide Endocrinology 1999; 140: 917-924.
84. Lim Ma, Stack CM, Cuasay K, Stone MM, et al. Regardless of genotype, offspring of VIP-deficient female mice exhibit developmental delays and deficits in social behavior. Int J Dev Neurosci 2008; 26: 423-434.
85. Tyrrell SLS. The appearance of NPY and VIP in sympathetic neuroblasts and subsequent alterations in their expression. J Neu-rosci 1994; 14: 4529-4547
86. Fraccaroli L, Alfieri J, Larocca L, et al. VIP modulates the pro-inflammatory maternal response inducing tolerance to trophoblast cells. Br J Pharmacol 2009; 156: 116-126.
87. Roca VRF, Calafat M, Perez Leiros C. Lack of nitric oxide-mediated regulation of amylase secretion stimulated by VIP in parotid glands of NOD mice. Int Immunopharmacol 2004; 4: 1837-1844.
88. Kong LRC, Peck AB, Vela-Roch N, et al. Inappropriate apoptosis of salivary and lacrimal gland epithelium of immunodeficient NOD-scid mice. Clin Exp Rheumatol 1998; 16: 675-681.
89. Robinson CPYS, Alford CE, Cooper C, et al. Elevated levels of cysteine protease activity in saliva and salivary glands of the nono-bese diabetic (NOD) mouse model for Sjögren syndrome. Proc Natl Acad Sci USA 1997; 94: 5767-5771.
90. Calafat M, Larocca L, Roca V, et al. Vasoactive intestinal peptide inhibits TNF-alpha-induced apoptotic events in acinar cells from nonobese diabetic mice submandibular glands. Arthr Res Ther 2009; 11: R53.
91. Hauk V, Calafat M, Larocca L, et al. Vasoactive intestinal pep-tide/vasoactive intestinal peptide receptor relative expression in salivary glands as one endogenous modulator of acinar cell apopto-sis in a murine model of Sjögren's syndrome. Clin Exp Immunol 2011; 166: 309-316.
92. Larocca L, Calafat M, Roca V, Franchi AM, Pérez C. VIP limits LPS-induced nitric oxide production through IL-10 in NOD mice macrophages. Int Immunopharmacol 2007; 7: 1343-1349.
93. Larocca L, Hauk V, Calafat M, et al. Modulation of macrophage inflammatory profile in pregnant nonobese diabetic (NOD) mice. Mol Cell Endocrinol 2011; 333: 112-118.
94. Jimeno R, Gomariz RP, Gutiérrez-Cañas I, Martínez C, Juarranz Y, Leceta J. New insights into the role of VIP on the ratio of T-cell subsets during the development of autoimmune diabetes. Immunol Cell Biol 2010; 88: 734-745.
95. Jimeno R, Leceta J, Martínez C, et al. Effect of VIP on the balance between cytokines and master regulators of activated helper T cells. Immunol Cell Biol 2012; 90: 178-186.